In this literature review we discuss the accumulating body of preclinical research which shows honokiol to have wide-ranging biological and clinically relevant effects, without appreciable toxicity. In vivo studies suggest that honokiol’s greatest value is in its multiple anticancer actions.
The current standard of care does not include detection of asymptomatic atherosclerosis. Instead, traditional risk factors are evaluated, the patient is put into a low-, medium-, or high-risk category, and lipid targets are determined by the clinician depending on the category. Thus, coronary artery disease is not detected early. We know that early detection of cancer saves lives. The same is true for atherosclerosis.